C4x Discovery Investors - C4XD

Stock Name	Stock Symbol	Market	Stock Type
C4x Discovery Holdings Plc	C4XD	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	-0.70	-3.12%	21.75	16:35:27

Open Price	Low Price	High Price	Close Price	Previous Close
21.90	21.20	21.90	21.75	22.45

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 13/4/2022 15:58 by t0pgrader In case anyone missed it, the INDIVIOR update on Phase 1 SAD of Orexin 1 Inhibitor INDV 2000) was published Feb 16 in the Q4 21 results. The report says Phase 1 MAD is on clinical hold at the instruction of the FDA based on "nonclinical findings from another similar development programme not sponsored by Indivior". However, "major progress" made on formulation and chemical development https://www.indivior.com/en/investors/results-reports-presentations Read Full Thread Follow Reply
Posted at 03/2/2022 07:41 by livewireplus RNS: Grant of Options and Directors Dealing Read Full Thread Follow Reply
Posted at 24/1/2022 18:04 by alloa2003 Savvy investors will start picking up cheap stock now - whoever "managed" this sale over the last week or so doesnt have a clue. They have smashed a share price and set the rumour mill going again. Read Full Thread Follow Reply
Posted at 13/12/2021 07:45 by alloa2003 Good solid results and plenty of little nuggets in there to keep investors interested but not the biggy I was personally expecting. Interesting to see they have made plans to conserve cash in the event that trials are extended, etc and they wont need to raise any more funds. I think C4XD is on the verge of becoming self-funding which is a massive step forward and should remove the previously constant threat of a fund raising. Interesting to see this element of the announcement about the previous fund raising:- Successful £15.0 million fundraise (before expenses) with a total of 107,142,858 Placing Shares and 99,169,286 Warrants issued to new and existing shareholders I believe the warrant strike price is 29p so if ever they needed additional funding these warrants could be exercised by, I would guess, mostly institutional shareholders - circa £30m. Dilutive but a useful drop back to have if they ever needed cash for any reason. All in all, steady as she goes I think and we await further developments within some of the very interesting historic and new areas mentioned. Read Full Thread Follow Reply
Posted at 07/11/2021 14:45 by alloa2003 Of course they can but do you often buy shares only traded on foreign markets? Do you think US investors are even aware that C4XD exists? Read Full Thread Follow Reply
Posted at 06/11/2021 20:12 by toffeeman >> alloa Do you really think that US investors cannot purchase shares in the UK? Read Full Thread Follow Reply
Posted at 20/4/2021 14:14 by alloa2003 New board appointment which to be fair is just what the doctor ordered:- "20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect. Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly. Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based. His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior. We welcome Simon to the Board and look forward to working closely with him." Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value." Read Full Thread Follow Reply
Posted at 12/4/2021 11:16 by astorcourt Clive has a video out today on the proactive investors site Read Full Thread Follow Reply
Posted at 12/4/2021 10:46 by alloa2003 Not sure what the attitude is all about? Firstly I presume we have all realised that todays deal was announced in Euros so when converted into dollars, like the Indivior deal, is a potential $571m. So it is approaching double the potential income of the first, huge, deal. The facts are the management of C4XD were tarnished when the first fund raising went wrong. They failed to agree a concrete price which then halved overnight and the troubles began. The fact the company is listed on AIM didnt help - not the best reputation. However, credit where it is due, the management have brought in influential private and institutional investors. Appears to me, assuming just one deal comes off, it is fully funded for a long long time. The shares have more than doubled recently, so news was probably leaking about short to medium term prospects. Like it or not, institutional (and large PIs) investors would not have poured millions into this company, even at rock bottom prices, if they didnt know more than we did. As of today we have two deals signed which could bring in a maximum of $865m in years to come. There is another partnership deal which seemed to be further down the road which has not yet been announced/agreed. There are also other molecules in the pipeline and no doubt more will emerge in the future. There have been upfront payments alread but its interesting that:- - The Indiviour deal is in the middle of clinical trials (so far so good) - Todays deal involves a VERY VERY early stage payment which suggests there was competition to get involved in this one So, egos aside, the management are:- - rebuilding their reputation - deals are finally being signed - potentially a lot more and maybe bigger ones in the pipeline Upfront payments, including todays are circa $20m, so thats leaves potential income streams going forward which could bring in another $845m. The company is capped at circa $124m which leaves potential for huge upside if only one of these products comes to market. Then we have the others in the deal pipeline, one nearing partner stage, and others in the future (both being worked on and not yet discovered). So all in all, while we need one treatment to be appoved for the final rubber stamping of the company, there is potentially HUGE upside. Not without risks, DYOR Read Full Thread Follow Reply
Posted at 12/4/2021 08:17 by jev1 Not all investors work off your impatience on a day trade or a one hour trade. It often tales time for news to be digested and reported in the wider media. Read Full Thread Follow Reply

Your Recent History

LSE

C4XD

C4x Discov..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20221204 22:27:20